Cannabis Law Report

FEBRUARY 10, 2022

Psilocybin’s therapeutic benefits are so promising that Denver, Colorado became the first city to decriminalize psilocybin in May 2019, and in 2020, Oregon passed Measure 109, which paved the road for a program allowing for legal manufacture, delivery, and administration of psilocybin to clients at supervised, licensed facilities in the state.

DEA 52

DEA Clinical Trials Policy Research and Development 52

Veriheal

JULY 12, 2021

Fortunately, congressional committees are fighting for medical cannabis access for veterans , and states are beginning to take measures to address their veterans , but what is the latest in research and what can one expect? Veterans can expect to find conflicting information regarding the efficacy of cannabis for their PTSD.

Treatment 104

Treatment Sleep Clinical Trials Data 104

Cannabis Law Report

JULY 4, 2019

The manuscript is part of EMMAC’s collaboration with Imperial College London, forged to deliver a long-term comprehensive research programme designed to inform and shape the future of the medical cannabis therapeutic industry. About EMMAC.

Cannabinoids 40

Cannabinoids Clinical Trials Chronic Pain Medicine 40

Cannabis Law Report

NOVEMBER 15, 2021

Although a limited number of CGTs are currently on the market, FDA officials predicted in 2019 that the agency will receive more than 200 investigational new drug applications per year for cell and gene therapies and that by 2025, it expects to have accelerated to 10 to 20 cell and gene therapy approvals per year 1. January 15, 2019.

Research and Development 52

Research and Development Therapy Clinical Trials Supply Chain 52

Cannabis Law Report

MARCH 2, 2020

The global march toward cannabis legalization has seemingly awoken another long dormant area of scientific interest: psychedelics as medicine. This renewed interest in psychedelics is being sparked by a pair of seemingly unrelated events. Shroom stocks may be a far better bet than cannabis. The rollercoaster starts here!

Medicine 59

Medicine Therapy DEA Pharmaceutical 59

Cannabis Law Report

JANUARY 4, 2022

(Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, has named Simon Allen as Chief Executive Officer and a member of the company’s Board of Directors, effective February 1 st , 2022.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Cannabinoids 52

Cannabis Law Report

SEPTEMBER 3, 2019

Awarded Australian Cannabis Industry 2019 Innovation Award. 03, 2019 (GLOBE NEWSWIRE) — MediPharm Labs Corp. We look forward to supporting Australian Licensed Producers with our specialized extraction capabilities and expertise to address this rapidly expanding cannabis market and growing consumer demand.”.

Pharmaceutical 45

Pharmaceutical Extraction Research and Development Supply Chain 45

Cannabis Law Report

NOVEMBER 16, 2021

As cleared by the FDA, the primary endpoint of the Phase 2 double-blind, placebo-controlled clinical trial is to achieve a reduction in the circulating levels of tumor necrosis factor-alpha (TNF-?), 1 [link] 2 October 9, 2019, Tumor Necrosis Factor (TNF) Inhibitor Drugs Market, Acumen Research and Consulting. 646) 421-9523.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

JANUARY 5, 2022

Forward-looking statements speak only as of the date they are made and MyMD disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise. 2 Goates et al. 3 Koon Yee-Lee et al. Robert Schatz. 646) 421-9523. rschatz@mymd.com www.mymd.com.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

Cannabis Law Report

SEPTEMBER 24, 2019

T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. Doctors can prescribe Epidyolex – an oral solution of cannabidiol, which comes from the cannabis plant – if they think it will help sufferers. What is Epidyolex?

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

NOVEMBER 24, 2019

The growth and management of psychedelics regulation will be equally chaotic, but we think just as fast as the cannabis sector. Upcoming Events. November 21, 2019. December 3, 2019. December 4, 2019. December 6, 2019. December 8-11, 2019. ” December 17, 2019. SMOKING CESSATION.

Therapy 59

Therapy Treatment Medicine Clinical Trials 59

Healer

DECEMBER 17, 2021

Drug interactions reported in the scientific literature most often occur at very high doses used in clinical trials of epilepsy and other conditions. Patients using warfarin need to have their blood INR level tested after adding THC-containing cannabis to their regimen. How Do CBD Drug Interactions Occur? CBD and Glaucoma.

CBD 98

CBD THC Conditions Medicine 98

Cannabis Law Report

OCTOBER 15, 2021

Xebra Brands Ltd. (“ Xebra “), a cannabis company, is pleased to announce that it has received final approval to list its common shares on the Canadian Securities Exchange. Xebra is a cannabis company, with global brands and intellectual property. More on Xebra www.xebrabrands.com. federally legalizes). THE NETHERLANDS.

Seed-To-Sale 52

Seed-To-Sale Cultivation Clinical Trials Cannabinoids 52

TheAnswerPage

JANUARY 11, 2022

As reviewed in a recent Forbes article, “a study of more than 400 health care professionals has revealed that most physicians lack knowledge of medicinal cannabis, with 65% saying that they have been asked about medical marijuana as a treatment for chronic pain but were unable to answer their patients’ questions” (1).

Patients 98

Patients Education Marijuana Therapy 98

Cannabis Law Report

SEPTEMBER 20, 2021

Delic expects to open 15 additional clinics across the country over the coming 18 months, further expanding access to millions who can benefit from psychedelic treatment for a variety of mental health conditions. Transaction Highlights.

Treatment 52

Treatment Media Research and Development Patients 52

Cannabis Law Report

DECEMBER 21, 2021

All three industries are target markets from Dalrada’s original expansion plan that started in 2019. With North America accounting for the most significant portion of the global healthcare services market at 40% (2019), market analysts expect growth at a CAGR of 7%, reaching $9,725.4 billion in 2019 Q3. billion in 2023.

Research and Development 52

Research and Development Supply Chain Data Business 52

Cannabis Law Report

JANUARY 20, 2022

ELE-Psilo program expected to enter clinical trials in Q2 2022 and to target the pressing need for rapid-acting antidepressants compatible with existing healthcare infrastructure and insurance. million SPAC sponsored by Silver Spike, an asset manager with deep expertise in health, wellness and cannabis investments. II is a $287.5

Therapy 52

Therapy Research and Development Business Access 52

Healer

DECEMBER 17, 2021

Drug interactions reported in the scientific literature most often occur at very high doses used in clinical trials of epilepsy and other conditions.[1]. Patients using warfarin need to have their blood INR level tested after adding THC-containing cannabis to their regimen. How Do CBD Drug Interactions Occur? CBD and Glaucoma.

CBD 52

CBD THC Conditions Medicine 52

Cannabis Law Report

JANUARY 7, 2020

2019 was an exciting year at iCAN. With our recent event in Cape Town, we have now brought CannaTech to every continent and helped build the cannabis footprint across the world. Five years of CannaTech have helped drive our mission to identify cannabis innovation and build the global cannabis ecosystem.

Events 59

Events Clinical Trials Decriminalization Education 59

Canna Law Blog

OCTOBER 5, 2022

We could see medical marijuana in Japan in the near future, which would be huge for Asian cannabis policy and the world. Passed in 1948, Japan’s Cannabis Control Act bans the import, export, production, sale, possession, and research of marijuana. Japan also ratified the Single Convention on Narcotic Drugs.

Marijuana 93

Marijuana Seed-To-Sale Clinical Trials Epilepsy 93

Project CBD

FEBRUARY 28, 2023

The combined total from both channels — $58,293,034 — does not include CBD sales in licensed cannabis dispensaries or CBD products, such as vapes, tinctures, gummies, and other edibles sold online. (E-commerce Sales appear to have peaked in 2019, when natural channel consumers spent more than $90.7 Accessed July 25, 2021.

CBD 144

CBD Seed-To-Sale Food Access 144

Puff Puff Post

SEPTEMBER 16, 2019

16, 2019 /CNW/ – Québec doctors have a new tool at their disposal for learning about medical cannabis and its viability as a treatment option for their patients. Logo : Santé Cannabis and Spectrum Therapeutics, the medical division of Canopy Growth (CNW Group/Canopy Growth Corporation). MONTREAL and SMITHS FALLS, ON, Sept.

Programs 108

Programs Research and Development Education Treatment 108

Project CBD

MAY 3, 2023

This transcript is adapted from CannMed’s weekly podcast , hosted by Ben Amirault, who recently interviewed Bonni Goldstein, MD, one of the country’s most respected and experienced medical cannabis physicians. Dr. Goldstein has treated thousands of patients with medical cannabis. CBG is not intoxicating or impairing.

Cannabinoids 209

Cannabinoids Sleep Clinical Trials CBD 209

Cannabis Law Report

OCTOBER 26, 2019

One such circumstance is a clinical trial. A clinical trial in Australia must have an Australian sponsor (whether it be an individual (e.g., Two of the avenues for supply of UTGs for clinical trials are the Clinical Trial Exemption (CTX) Scheme and the Clinical Trial Notification (CTN) Scheme.

Clinical Trials 45

Clinical Trials Medicine Research and Development Compliance 45

The Joint Blog

APRIL 21, 2020

This is according to a study published in the Journal of Clinical Medicine Research and epublished by the U.S. For the study researchers with the Nordic Cannabis Research Institute in Denmark reviewed 25 clinical trials assessing the safety and efficacy of CBD in various populations. National Institute of Health.

Clinical Trials 52

Clinical Trials CBD Safety Patients 52

Cannabis Law Report

MARCH 29, 2020

According to Vividata’s National Cannabis Consumer Study , 70% of consumers are not sure they know the difference between THC and CBD. Moreover, quality remains the top criterion in selecting a cannabis product for purchase. Setting Standards for Cannabis Research Studies . Product Quality in Manufacturing.

Compliance 69

Compliance Compliance Supply Chain Research and Development 69

Cannabis Law Report

APRIL 8, 2022

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. For over three decades, we’ve been working to achieve mass mental health throughout the United States, Canada, and Europe.

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Puff Puff Post

SEPTEMBER 16, 2019

16, 2019 /CNW/ – Québec doctors have a new tool at their disposal for learning about medical cannabis and its viability as a treatment option for their patients. Logo : Santé Cannabis and Spectrum Therapeutics, the medical division of Canopy Growth (CNW Group/Canopy Growth Corporation). MONTREAL and SMITHS FALLS, ON, Sept.

Programs 40

Programs Research and Development Education Treatment 40

Cannabis Law Report

NOVEMBER 24, 2021

Medical publications, are, in the main fairly positive toward cannabis. Published by The Journal of Cannabis Research. Medicinal cannabis has been legalised for use for a range of specified medical conditions in Australia since 2016. At the same time, the outlook on cannabis research data is largely positive. Background.

Research and Development 52

Research and Development Medicine Access Media 52

CannaMD

MARCH 8, 2020

Few randomized clinical trials have been conducted or are planned to explore the effects of marijuana on cardiovascular risk. Screening and testing for use of marijuana are encouraged in clinical settings, especially in the care of young patients presenting with cardiovascular disease. a heart attack).

Patients 79

Patients Marijuana Research and Development Clinical Trials 79

Cannabis Law Report

NOVEMBER 7, 2019

Cannatrek’s Seed to Patient business model combines cutting edge cultivation expertise and world class manufacturing practices to deliver high quality medicinal cannabis oil formulations and medicinal strains of dried flowers at a significantly lower cost to patients and retailers.

Medicine 40

Medicine Patients Research and Development Clinical Trials 40

The Cannigma

MAY 7, 2021

Listen & Subscribe: When it comes to regulating and producing medicalized cannabis products, different countries have a variety of approaches. The American field of medicalized cannabis has followed a very different path to Europe. . The Cannabis Enigma podcast is a co-production of The Cannigma and Americans for Safe Access.

Supply Chain 120

Supply Chain Patients Access Hemp 120

Cannabis Law Report

JULY 15, 2022

The first Australian company to be licensed to cultivate and manufacture medicinal marijuana has praised the Federal Government’s plan to allow exports of cannabis-based medicines. Secrecy has surrounded a media visit to Queensland’s first licensed cannabis farm, which is nearing completion on the Sunshine Coast.

Medicine 52

Medicine Patients Media Supply Chain 52

Cannabis Law Report

JANUARY 18, 2019

14, 2019 /PRNewswire/ — The world’s top cannabis industry leaders will convene in an unprecedented gathering in Davos, Switzerland from January 22-25. Cannabis is part and parcel of the next wave of globalization and a serious discussion in Davos could not be more timely,” said iCAN’s Saul Kaye.

Research and Development 40

Research and Development Clinical Trials Extraction Therapy 40

Cannabis Law Report

JUNE 4, 2021

Rick, and MAPS, have published hundreds of research papers, articles, and reports over the past several decades in addition to participation in dozens of clinical trials and international studies. a leading biotech company in the hemp and cannabis industries. in/rickdoblin/ [link]. in/paul-stamets-14272910 [link]. in/ronanlevy/.

Research and Development 51

Research and Development Medicine Treatment Pharmaceutical 51

Cannabis Law Report

OCTOBER 17, 2019

As more countries legalize or decriminalize the cultivation, manufacture, sale, and use of cannabis, companies across a variety of industries are looking for opportunities to capitalize on this emerging market. This white paper offers a primer to the complex and confusing global cannabis industry as it stands today.

Law 40

Law Seed-To-Sale Hemp Recreational 40

Cannabis Law Report

DECEMBER 30, 2019

NORML write, “2019 has been a monumental year for cannabis reform across the United States. Over 60 cannabis-related bills were signed into law in states across the country. This report contains a detailed summary of 2019’s federal and state legislative victories.” ” Director’s Statement.

Legislation 59

Legislation Patients Access Banking 59